These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18178159)

  • 1. T cell precursor frequency differentially affects CTL responses under different immune conditions.
    Ye Z; Ahmed KA; Huang J; Xie Y; Munegowda MA; Xiang J
    Biochem Biophys Res Commun; 2008 Mar; 367(2):427-34. PubMed ID: 18178159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
    Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
    Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
    Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
    Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
    Ke Y; Kapp JA
    J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspergillus fumigatus extract differentially regulates antigen-specific CD4+ and CD8+ T cell responses to promote host immunity.
    Tao J; Segal BH; Eppolito C; Li Q; Dennis CG; Youn R; Shrikant PA
    J Leukoc Biol; 2006 Sep; 80(3):529-37. PubMed ID: 16793916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL.
    Inoue S; Golding B; Scott D
    Vaccine; 2005 Feb; 23(14):1730-8. PubMed ID: 15705479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA.
    Steinaa L; Rasmussen PB; Gautam A; Mouritsen S
    Scand J Immunol; 2008 Feb; 67(2):113-20. PubMed ID: 18201366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
    Wang W; Golding B
    Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
    Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
    Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
    Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
    Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
    Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
    Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
    Xie Y; Zhang X; Zhao T; Li W; Xiang J
    Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
    Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
    Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.